Ocular
inflammation is one of the consequences of
infection with the protozoan parasite Toxoplasma gondii. Even if lesions are self-healing in immunocompetent persons, they pose a lifetime risk of reactivation and are a serious threat to vision. As there are virtually no immunological data on reactivating
ocular toxoplasmosis, we established a model of direct
intravitreal injection of parasites in previously infected mice with a homologous type II strain. Two different mouse strains with variable ability to control
retinal infection were studied in order to describe protective and deleterious reaction patterns. In Swiss-Webster mice, which are already relatively resistant to primary
infection, no peak of parasite load was observed upon
reinfection. In contrast, the susceptible inbred strain C57BL/6 showed high parasite loads after 7 days, as well as marked deterioration of
retinal architecture. Both parameters were back to normal on day 21. C57BL/6 mice also reacted with a strong local production of inflammatory and Th1-type
cytokines, like
interleukin-6 (IL-6),
IL-17A, and
gamma interferon (IFN-γ), while Swiss-Webster mice showed only moderate expression of the Th2
cytokine IL-31. Interestingly, rapid intraocular production of anti-Toxoplasma
antibodies was observed in Swiss-Webster but not in C57BL/6 mice. We then localized the cellular source of different immune mediators within the retina by immunofluorescence. Finally, neutralization experiments of IFN-γ or
IL-6 demonstrated the respective protective and deleterious roles of these
cytokines for parasite control and
retinal integrity during
reinfection. In conclusion, we developed and immunologically characterized a promising mouse model of reactivating
ocular toxoplasmosis.